Trial intelligence / Profile preview

Dorzolamide vs Timolol on Optic Disk Blood Flow in Glaucoma

NCT00991822Phase 3

Key facts

Status: Completed
Start: May 1999
Primary completion: Dec 2001
Countries: 1
Sponsor: Medical University of Vienna
Modality: Small Molecules

Drugs: dorzolamide
Conditions: open-angle glaucoma (OAG)ocular hypertension

Overview

Phase 3, randomised, double-blind trial of dorzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Percent change over baseline of optic disk blood flow at 3 months and Percent change over baseline of fundus pulsation amplitude at 3 months. Started May 1999; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Dorzolamide
Dorzolamide 2%
Timolol
Timolol 0.5%

Who it enrols

Patients older than 19 with primary open angle glaucoma or ocular hypertension (IOP > 22 mmHg). Excludes patients with severe renal impairment, heart block, bradycardia, asthma, COPD, or CHF.

Endpoints

Primary

Percent change over baseline of optic disk blood flow3 months
Percent change over baseline of fundus pulsation amplitude3 months

Beyond the preview

Go deeper on NCT00991822.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00991822.